2 results
Approved WMORecruiting
In 2013 the Boston Scientific VERCISE System has obtained regulatory approval for use in the European Union, CE mark was granted for the treatment of intractable primary and secondary dystonia.The objective of the study is to compile characteristics…
Approved WMORecruiting
The primary purpose of the study is to determine the efficacy and safety of T-DXd compared with investigator*s choice single agent chemotherapy in the target population.